First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

AIMS: The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS‐962212, a first‐in‐class factor XIa inhibitor, in Japanese and non‐Japanese healthy subjects. METHODS: This was a randomized, placebo‐controlled, double‐blind, sequential, ascending‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Vidya, Luettgen, Joseph M., Wang, Zhaoqing, Frost, Charles E., Yones, Cynthia, Russo, Cesare, Lee, John, Zhao, Yue, LaCreta, Frank P., Ma, Xuewen, Knabb, Robert M., Seiffert, Dietmar, DeSouza, Mary, Mugnier, Pierre, Cirincione, Brenda, Ueno, Takayo, Frost, Robert J. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903252/
https://www.ncbi.nlm.nih.gov/pubmed/29346838
http://dx.doi.org/10.1111/bcp.13520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903252/
https://www.ncbi.nlm.nih.gov/pubmed/29346838
http://dx.doi.org/10.1111/bcp.13520

Ejemplares similares